IL6 and hepatocellular carcinoma: Then, they employed lipid/calcium/phosphate NPs for the delivery of plasmid DNA encoding an IL-6 protein in the CCRK knockout orthotopic HCC model using CRISPR/Cas9 technology, and found that targeted inhibition of CCRK enhanced the efficacy of anti-PD-L1 in HCC via abrogation of MDSC immunosuppression [112].